Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery
NCT ID: NCT01799876
Last Updated: 2019-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2013-02-28
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee
NCT02524509
Autologous Chondrocyte Implantation in the Patellofemoral Joint
NCT00212849
Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid
NCT02285725
Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures
NCT01947374
Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee
NCT06216756
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Some patients will have the fat removed and cells inserted in their knee, and other patients will not have the fat removed or cells inserted. To which group patients are assigned is determined by a random process, similar to flipping a coin. The surgery is the same in all other ways for all patients.
Participation will require attending regularly scheduled postoperative visits, having 3 MRI tests, and answering a short survey. No additional visits other beyond those normally scheduled for postsurgical care are required.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autologous Cell
Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
Autologous Cell
Control
Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
Standard microfracture arthroscopic surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Cell
Standard microfracture arthroscopic surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Osteochondral defect Grade III or IV
* Age 18 to 68 years
* Sufficient subcutaneous adipose tissue to yield 20-30 cc of lipoaspirate
* Written informed consent
* Ability to speak, read and write English or Spanish
Exclusion Criteria
* Evidence of malignant disorder/neoplasm in past 24 months
* History of basal cell carcinoma
* History of smoking and not committed to give up
* Chronic skin conditions
* Connective, metabolic or skin disease
* Evidence of active infection
* Pregnancy or lactating for female subjects
* Diabetes Type I or II
* Current steroid use
* Immunosuppressive medication
* Renal failure (creatine \> 1.8 mg/dL)
* Hepatic failure (AST, ALT \>2 times normal values; bilirubin \>2.0 mg/dL)
* Inflammatory joint diseases of the knee that indicate additional, conflating therapies
* Joint infection within the past 6 months
* Meniscal resection of greater than 50% prior to, or at time of procedure
* Uncorrected joint instability
* Joint malalignment \> 5 degrees
18 Years
68 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InGeneron, Inc.
INDUSTRY
Fondren Orthopedic Group L.L.P.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert L Burke, MD
Role: PRINCIPAL_INVESTIGATOR
Fondren Orthopedic Group L.L.P.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondren Orthopedic Group, L.L.P.
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FOG-TOH125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.